Coherus Biosciences Stock Earnings Reports

Coherus Oncology reiterated a three-part strategy centered on LOQTORZI (their next‑generation PD‑1 inhibitor) as both a revenue generator in nasopharyngeal cancer (NPC) and a multiplier when combined with pipeline assets (notably casdozokitug and tagmokitug). Management projects LOQTORZI-related commercial milestones of ~$15M/quarter in 2026, $30–35M/quarter in 2027, and a peak market share translating to ~$175M/year (about $44M/quarter) by 2028. Clinical progress: the randomized CATALYST‑202 casdozokitug study in first‑line hepatocellular carcinoma (72 patients) has completed accrual with initial data expected around mid‑year; multiple tagmokitug (CCR8 antibody) cohorts across head & neck, upper GI, ESCC, MSS CRC and a J&J pasritamig (T‑cell engager) prostate cohort are accruing, with several initial readouts anticipated mid‑year and into H2. Scientific emphasis: the company is prioritizing biomarker work (IL‑27, circulating tumor DNA) and pharmacology to demonstrate contribution of components and identify responsive subgroups. Commercial update: Q1 LOQTORZI net sales were $11.8M (up 61% YoY), but Q1 was impacted by severe winter storms and typical seasonality; new patient starts hit a record high and prescribing breadth/depth increased, with plans to reduce chemo‑only use and off‑label PD‑1 prescribing through targeted education and data‑driven field engagement. Financials: net proceeds of $54M from a follow‑on equity offering; cash, cash equivalents and investments of $167M at quarter end; R&D and SG&A expenses declined YoY due to disciplined spending and exit from biosimilars. Risks/competitive landscape: CCR8 programs across the industry are showing mixed results — some companies paused programs (attributed to suboptimal drug properties), while others advance; Coherus positions tagmokitug as having favorable pharmacology but acknowledges biological and development challenges with CCR8 targeting.